Skip to main content

Contractor intelligence · computed from public award records

MAGICPHARMA

Awards won
40
Known value
USD 4.2M
First award
11 Nov 2018
Most recent
22 Sept 2019

Wins by funder

FunderAwardsKnown valueMost recent
World Bank40USD 4.2M22 Sept 2019

Where the work is

EG · 40

Sources

The most recent award records behind the figures above. Every number on this page is computed from records like these — nothing is estimated or editorial.

  • Purchase of hepatitis c drugs · 22 Sept 2019 · USD 108K · World Bank
  • alltechnical offers are acceptable The Sofosbuvir 400mg ,Daclatasvir 60 mgand Ribavirin drugs · 22 Jul 2019 · USD 109K · World Bank
  • alltechnical offers are acceptable The Sofosbuvir 400mg ,Daclatasvir 60 mgand Ribavirin drugs · 22 Jul 2019 · USD 107K · World Bank
  • Purchase of hepatitis c drugs · 22 Jul 2019 · USD 109K · World Bank
  • alltechnical offers are acceptable The Sofosbuvir 400mg ,Daclatasvir 60 mgand Ribavirin drugs · 22 Jul 2019 · USD 105K · World Bank
  • alltechnical offers are acceptable The Sofosbuvir 400mg ,Daclatasvir 60 mgand Ribavirin drugs · 22 Jul 2019 · USD 106K · World Bank
  • alltechnical offers are acceptable The Sofosbuvir 400mg ,Daclatasvir 60 mgand Ribavirin drugs · 22 Jul 2019 · USD 106K · World Bank
  • alltechnical offers are acceptable The Sofosbuvir 400mg ,Daclatasvir 60 mgand Ribavirin drugs · 22 Jul 2019 · USD 106K · World Bank
  • all technical offers are acceptable for The Sofosbuvir 400mg ,Daclatasvir 60 mg drugs · 22 Jul 2019 · USD 107K · World Bank
  • all technical offers are acceptable for The Sofosbuvir 400mg ,Daclatasvir 60 mg drugs · 13 Jun 2019 · USD 109K · World Bank
  • alltechnical offers are acceptable The Sofosbuvir 400mg ,Daclatasvir 60 mgand Ribavirin drugs · 13 Jun 2019 · USD 110K · World Bank
  • all technical offers are acceptable for The Sofosbuvir 400mg ,Daclatasvir 60 mg drugs · 13 Jun 2019 · USD 111K · World Bank
  • alltechnical offers are acceptable The Sofosbuvir 400mg ,Daclatasvir 60 mgand Ribavirin drugs · 13 Jun 2019 · USD 111K · World Bank
  • Purchase of hepatitis c drugs (Sofosbuvir400mg ,Daclatasvir 60 mg drugs ) · 13 Jun 2019 · USD 109K · World Bank
  • alltechnical offers are acceptable The Sofosbuvir 400mg ,Daclatasvir 60 mgand Ribavirin drugs · 13 Jun 2019 · USD 109K · World Bank
  • alltechnical offers are acceptable The Sofosbuvir 400mg ,Daclatasvir 60 mgand Ribavirin drugs · 13 Jun 2019 · USD 109K · World Bank
  • all technical offers are accepted for The Sofosbuvir 400mg , Daclatasvir 60 mg drugs · 11 Nov 2018 · USD 96K · World Bank
  • all technical offers are acceptable for The Sofosbuvir 400mg ,Daclatasvir 60 mg drugs · 11 Nov 2018 · USD 96K · World Bank
  • all technical offers are accepted for The Sofosbuvir 400mg , Daclatasvir 60 mg drugs · 11 Nov 2018 · USD 96K · World Bank
  • all technical offers are accepted for The Sofosbuvir 400mg , Daclatasvir 60 mg drugs · 11 Nov 2018 · USD 96K · World Bank

Method

Computed from 40 award records ingested from official disclosure sources (World Bank, Inter-American Development Bank, and published contract-award notices). Values are shown in USD where the source published one; entity identity is resolved conservatively and reviewed. GLODA is not affiliated with any funder or contractor shown. Last computed 15 Sept 2026.